MacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Call Transcript

Scott Koenig: Yes, I mean, I would say the most encouraging data was obviously a small data set, and they were talking about expansion in other tumor types is that of the nine patients with small cell lung cancer, seven had an objective responses, which fits the data that [Indiscernible] has discussed also in the small cell population. So clearly, this is a histological type that we are certainly considering adding to the types being tested. We — as you may recall, we have only had one patient with small cell cancer in our dose escalation, who actually did very well on vobra at a lower dose that patient was on treatment for over six months with tumor shrinkage. I didn’t have an objective response, but really responded well to the therapy. So, clearly, that opens up for us a confirmation that a small cell may be an indication we should also pursue.

Silvan Tuerkcan: Great. Well, thanks for taking my question.

Scott Koenig: Thank you.

Operator: Thank you. Our next question comes from Boris Peaker with TD Cowen. Your line is open.

Unidentified Analyst: Hi. My name is [Indiscernible] for Boris Peaker. I would like to ask. How confident for vobra duo, how confident are you that the two doses that you’re testing will give you the idea of those moving forward? And you think about the registrational trial do you expect a further dose modification is needed? Thank you.

Scott Koenig: So, as any experiment being conducted, you go with the data you have and you have a hypothesis and we feel that the doses we selected were the right ones. This was based on a full analysis of the data and all the expansion cohorts with regard to side effect profiles, tumor responses, pharmacokinetics. And so we tried to book end based on what the real exposure was in patients as commented on earlier, the majority of patients had dose reductions. So, we feel that we’ve picked the two doses that should give us more clarity with regard to an improved safety profile and activity profile. So, as much as that can guide us — we’re hoping that was the right selection and the right answer. And if we have to make modifications in some ways, subsequently once we get the data, we’ll do it if the drug looks both active as well as relatively safe.

Unidentified Analyst: Got it. Thank you for taking my question.

Operator: Thank you. [Operator Instructions] There are no further questions. I’d like to turn the call back over to Dr. Koenig for closing remarks.

Scott Koenig: Well, thank you very much, operator and thank you everyone for participating in our call today. We look forward to providing further updates both on our clinical and preclinical pipeline in the coming months. Have a good day.

Operator: Thank you for your participation. This does conclude the program and you may now disconnect. Everyone, enjoy the rest of your day.